BILLERICA, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL”, NASDAQ: SQL), a technology company providing life sciences instrumentation and research services, today announced the establishment of a two-year Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Justice’s Federal Bureau of Investigation (FBI). Under this CRADA, SeqLL and the FBI Laboratory Division (FBI LD) will seek to evaluate and determine the forensic capabilities of direct RNA sequencing using SeqLL’s True Single Molecule Sequencing (tSMS®) platform.
The FBI LD and SeqLL will collaborate with a goal of producing an assay for forensic body fluid identification, without compromising traditional STR or DNA sequence analysis. This agreement is among the first times the FBI is utilizing the CRADA mechanism to further develop laboratory capabilities.
CRADAs enable the sharing of resources and expertise for collaborative research that advances the FBI mission. “Body fluid identification can provide investigative context and have probative value. We are excited to collaborate with SeqLL to evaluate the potential of this capability in forensic casework,” said Eric Pokorak, Assistant Director, FBI Laboratory Division.
“We are delighted to be working with a motivated and knowledgeable partner, such as the FBI LD. We appreciate the opportunity this CRADA provides, to methodically develop forensic applications utilizing SeqLL’s technology,” said Daniel Jones, SeqLL CEO and Founder. “We look forward to demonstrating how single-molecule, PCR-free approaches are ideally suited for this space.”
About the FBI’s Laboratory Division
The FBI conducts research and development activities as a recognized federal laboratory. This CRADA will support the FBI LD, a division within the Scientific and Technology Branch, whose mission is to collect, analyze and share timely scientific and technical information. The FBI LD’s primary locations are the FBI Academy in Quantico, VA and FBI Redstone in Huntsville, AL.
About SeqLL Inc.
SeqLL Inc. (“SeqLL”) is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple “omics” fields. The Company leverages its expertise with the True Single Molecule Sequencing (“tSMS®”) platform to empower scientists and researchers with improved genetic tools to better understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with today’s precision medicine.
Forward Looking Statements
This press release contains certain forward-looking statements, including those related to the applicability and viability of the Company’s technology to quantifying RNA molecules from blood and other statements that are predictive in nature. Forward-looking statements are based on the Company's current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in the Company's filings with the Securities and Exchange Commission, including its registration statement on Form S-1, as amended, under the caption “Risk Factors.”
Chief Business Officer
Tel: +1 (508) 847-7711